"Global CAR T Cell Therapy Market Overview:
Global CAR T Cell Therapy Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global CAR T Cell Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of CAR T Cell Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the CAR T Cell Therapy Market:
The CAR T Cell Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for CAR T Cell Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study CAR T Cell Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, CAR T Cell Therapy market has been segmented into:
CD19
BCMA
HER2
GD2
CD20
CD22
CD30
CD33
HER1
Others (CLDN18
etc.
By Application, CAR T Cell Therapy market has been segmented into:
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The CAR T Cell Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the CAR T Cell Therapy market.
Top Key Players Covered in CAR T Cell Therapy market are:
Bristol-Myers Squibb Company
Johnson & Johnson Servicesinc.
Novartis AG
CARsgenTherapeutics Co.
Ltd
Aurora Biopharma
Legend Biotech
Gilead Sciencesinc.
Pfizer Inc.
bluebird bioinc.
Sorrento Therapeuticsinc.
Mustang Bio
Fate Therapeutics
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: CAR T Cell Therapy Market by Type
4.1 CAR T Cell Therapy Market Snapshot and Growth Engine
4.2 CAR T Cell Therapy Market Overview
4.3 CD19
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 CD19: Geographic Segmentation Analysis
4.4 BCMA
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 BCMA: Geographic Segmentation Analysis
4.5 HER2
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 HER2: Geographic Segmentation Analysis
4.6 GD2
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 GD2: Geographic Segmentation Analysis
4.7 CD20
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 CD20: Geographic Segmentation Analysis
4.8 CD22
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 CD22: Geographic Segmentation Analysis
4.9 CD30
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 CD30: Geographic Segmentation Analysis
4.10 CD33
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 CD33: Geographic Segmentation Analysis
4.11 HER1
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 HER1: Geographic Segmentation Analysis
4.12 Others (CLDN18
4.12.1 Introduction and Market Overview
4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.12.3 Key Market Trends, Growth Factors and Opportunities
4.12.4 Others (CLDN18: Geographic Segmentation Analysis
4.13 etc.
4.13.1 Introduction and Market Overview
4.13.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.13.3 Key Market Trends, Growth Factors and Opportunities
4.13.4 etc.: Geographic Segmentation Analysis
Chapter 5: CAR T Cell Therapy Market by Application
5.1 CAR T Cell Therapy Market Snapshot and Growth Engine
5.2 CAR T Cell Therapy Market Overview
5.3 Acute Lymphocytic Leukemia
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Acute Lymphocytic Leukemia: Geographic Segmentation Analysis
5.4 Chronic Lymphocytic Leukemia
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Chronic Lymphocytic Leukemia: Geographic Segmentation Analysis
5.5 Diffuse Large B-cell Lymphoma (DLBCL
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Diffuse Large B-cell Lymphoma (DLBCL: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 CAR T Cell Therapy Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BRISTOL-MYERS SQUIBB COMPANY
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 JOHNSON & JOHNSON SERVICESINC.
6.4 NOVARTIS AG
6.5 CARSGENTHERAPEUTICS CO.
6.6 LTD
6.7 AURORA BIOPHARMA
6.8 LEGEND BIOTECH
6.9 GILEAD SCIENCESINC.
6.10 PFIZER INC.
6.11 BLUEBIRD BIOINC.
6.12 SORRENTO THERAPEUTICSINC.
6.13 MUSTANG BIO
6.14 FATE THERAPEUTICS
Chapter 7: Global CAR T Cell Therapy Market By Region
7.1 Overview
7.2. North America CAR T Cell Therapy Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 CD19
7.2.4.2 BCMA
7.2.4.3 HER2
7.2.4.4 GD2
7.2.4.5 CD20
7.2.4.6 CD22
7.2.4.7 CD30
7.2.4.8 CD33
7.2.4.9 HER1
7.2.4.10 Others (CLDN18
7.2.4.11 etc.
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Acute Lymphocytic Leukemia
7.2.5.2 Chronic Lymphocytic Leukemia
7.2.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe CAR T Cell Therapy Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 CD19
7.3.4.2 BCMA
7.3.4.3 HER2
7.3.4.4 GD2
7.3.4.5 CD20
7.3.4.6 CD22
7.3.4.7 CD30
7.3.4.8 CD33
7.3.4.9 HER1
7.3.4.10 Others (CLDN18
7.3.4.11 etc.
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Acute Lymphocytic Leukemia
7.3.5.2 Chronic Lymphocytic Leukemia
7.3.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe CAR T Cell Therapy Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 CD19
7.4.4.2 BCMA
7.4.4.3 HER2
7.4.4.4 GD2
7.4.4.5 CD20
7.4.4.6 CD22
7.4.4.7 CD30
7.4.4.8 CD33
7.4.4.9 HER1
7.4.4.10 Others (CLDN18
7.4.4.11 etc.
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Acute Lymphocytic Leukemia
7.4.5.2 Chronic Lymphocytic Leukemia
7.4.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific CAR T Cell Therapy Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 CD19
7.5.4.2 BCMA
7.5.4.3 HER2
7.5.4.4 GD2
7.5.4.5 CD20
7.5.4.6 CD22
7.5.4.7 CD30
7.5.4.8 CD33
7.5.4.9 HER1
7.5.4.10 Others (CLDN18
7.5.4.11 etc.
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Acute Lymphocytic Leukemia
7.5.5.2 Chronic Lymphocytic Leukemia
7.5.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa CAR T Cell Therapy Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 CD19
7.6.4.2 BCMA
7.6.4.3 HER2
7.6.4.4 GD2
7.6.4.5 CD20
7.6.4.6 CD22
7.6.4.7 CD30
7.6.4.8 CD33
7.6.4.9 HER1
7.6.4.10 Others (CLDN18
7.6.4.11 etc.
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Acute Lymphocytic Leukemia
7.6.5.2 Chronic Lymphocytic Leukemia
7.6.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America CAR T Cell Therapy Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 CD19
7.7.4.2 BCMA
7.7.4.3 HER2
7.7.4.4 GD2
7.7.4.5 CD20
7.7.4.6 CD22
7.7.4.7 CD30
7.7.4.8 CD33
7.7.4.9 HER1
7.7.4.10 Others (CLDN18
7.7.4.11 etc.
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Acute Lymphocytic Leukemia
7.7.5.2 Chronic Lymphocytic Leukemia
7.7.5.3 Diffuse Large B-cell Lymphoma (DLBCL
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
CAR T Cell Therapy Scope:
|
Report Data
|
CAR T Cell Therapy Market
|
|
CAR T Cell Therapy Market Size in 2025
|
USD XX million
|
|
CAR T Cell Therapy CAGR 2025 - 2032
|
XX%
|
|
CAR T Cell Therapy Base Year
|
2024
|
|
CAR T Cell Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Bristol-Myers Squibb Company, Johnson & Johnson Servicesinc., Novartis AG, CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciencesinc., Pfizer Inc., bluebird bioinc., Sorrento Therapeuticsinc., Mustang Bio, Fate Therapeutics.
|
|
Key Segments
|
By Type
CD19
BCMA
HER2
GD2
CD20
CD22
CD30
CD33
HER1
Others (CLDN18
etc.
By Applications
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL
|
